1α,25-dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells

Yanhong Wu, James D. Haugen, Alan R. Zinsmeister, Rajiv Kumar

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

To determine whether the inhibition of human osteoblast growth mediated by 1α,25-dihydroxyvitamin D3 (1α,25(OH)D3) occurs as a result of changes in transforming growth factor (TGF) and TGF receptor synthesis, we examined the effects of 1α,25(OH)2D3 on the synthesis of TGFβ and TGF-β receptors. Treatment with 1α,25(OH)2D3, but not vehicle, increased TGF-β2 concentrations in human osteoblast cell supernantants in a dose- and time-dependent manner. The increase in TGF-β2 concentrations was associated with an inhibition of osteoblast cell growth; antibodies directed against transforming growth factor β partially blocked the inhibition of cellular growth mediated by 1α,25(OH)2D3. TGF-β2 gene transcription and TGF-β2 mRNA concentrations were increased in 1α,25(OH)D3 but not in vehicle-treated cells. 1α,25(OH)2D3 increased TGF-β type I and type II receptor mRNA levels in osteoblasts. Increased expression of TGF-β2 and TGF-β receptors by 1α,25(OH)2D3 might account for the inhibition of human osteoblast growth seen following 1α,25(OH)2D3 treatment.

Original languageEnglish (US)
Pages (from-to)734-739
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume239
Issue number3
DOIs
StatePublished - Oct 29 1997

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of '1α,25-dihydroxyvitamin D<sub>3</sub> increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells'. Together they form a unique fingerprint.

  • Cite this